ࡱ> '` Vbjbj{P{P 9|::rN%!!!8!!L)E26"L""n"n"n"###DDDDDDD$[FhHD+#"#++Dn"n"aDZ1Z1Z1+n"n"DZ1+DZ1Z1B|Cn"*" /:س!6.ZCtD4D0)ECI/I$CCfIDD0#%lZ1['$(%###DD0###)E++++d& d&  The CAUSES & EFFECTS of CIRRHOSIS of the LIVER What is cirrhosis? Cirrhosis is a condition in which the liver slowly deteriorates and malfunctions due to chronic injury. Scar tissue replaces healthy liver tissue, partially blocking the flow of blood through the liver. Scarring also impairs the livers ability to * control infections * remove bacteria and toxins from the blood * process nutrients, hormones, and drugs * make proteins that regulate blood clotting * produce bile to help absorb fatsincluding cholesteroland fat-soluble vitamins  A healthy liver is able to regenerate most of its own cells when they become damaged. With end-stage cirrhosis, the liver can no longer effectively replace damaged cells. A healthy liver is necessary for survival. Drawing of the torso showing the digestive system, with the liver highlighted and labeled. The liver and digestive system. Cirrhosis is the twelfth leading cause of death by disease, accounting for 27,000 deaths each year (immediately below). The condition affects men slightly more often than women. Minio AM, Heron MP, Murphy SL, Kochanek KD. Deaths: Final data for 2004. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/nchs/data/nvsr/nvsr55/nvsr55_19.pdf. Updated October 10, 2007. Accessed January 20, 2008. What CAUSES cirrhosis? Cirrhosis has various causes. In the United States, heavy alcohol consumption and chronic hepatitis C have been the most common causes of cirrhosis. Obesity is becoming a common cause of cirrhosis, either as the sole cause or in combination with alcohol, hepatitis C, or both. Many people with cirrhosis have more than one cause of liver damage. Cirrhosis is not caused by trauma to the liver or other acute, or short-term, causes of damage. Usually years of chronic injury are required to cause cirrhosis. Alcohol-related liver disease. Most people who consume alcohol do not suffer damage to the liver. But heavy alcohol use over several years can cause chronic injury to the liver. The amount of alcohol it takes to damage the liver varies greatly from person to person. For women, consuming two to three drinksincluding beer and wineper day and for men, three to four drinks per day, can lead to liver damage and cirrhosis. In the past, alcohol-related cirrhosis led to more deaths than cirrhosis due to any other cause. Deaths caused by obesity-related cirrhosis are increasing. Chronic hepatitis C. The hepatitis C virus is a liver infection that is spread by contact with an infected persons blood. Chronic hepatitis C causes inflammation and damage to the liver over time that can lead to cirrhosis. Chronic hepatitis B and D. The hepatitis B virus is a liver infection that is spread by contact with an infected persons blood, semen, or other body fluid. Hepatitis B, like hepatitis C, causes liver inflammation and injury that can lead to cirrhosis. The hepatitis B vaccine is given to all infants and many adults to prevent the virus. Hepatitis D is another virus that infects the liver and can lead to cirrhosis, but it occurs only in people who already have hepatitis B. Nonalcoholic fatty liver disease (NAFLD). In NAFLD, fat builds up in the liver and eventually causes cirrhosis. This increasingly common liver disease is associated with obesity, diabetes, protein malnutrition, coronary artery disease, and corticosteroid medications. Autoimmune hepatitis. This form of hepatitis is caused by the bodys immune system attacking liver cells and causing inflammation, damage, and eventually cirrhosis. Researchers believe genetic factors may make some people more prone to autoimmune diseases. About 70 percent of those with autoimmune hepatitis are female. Diseases that damage or destroy bile ducts. Several different diseases can damage or destroy the ducts that carry bile from the liver, causing bile to back up in the liver and leading to cirrhosis. In adults, the most common condition in this category is primary biliary cirrhosis, a disease in which the bile ducts become inflamed and damaged and, ultimately, disappear. Secondary biliary cirrhosis can happen if the ducts are mistakenly tied off or injured during gallbladder surgery. Primary sclerosing cholangitis is another condition that causes damage and scarring of bile ducts. In infants, damaged bile ducts are commonly caused by Alagille syndrome or biliary atresia, conditions in which the ducts are absent or injured. Inherited diseases. Cystic fibrosis, alpha-1 antitrypsin deficiency, hemochromatosis, Wilson disease, galactosemia, and glycogen storage diseases are inherited diseases that interfere with how the liver produces, processes, and stores enzymes, proteins, metals, and other substances the body needs to function properly. Cirrhosis can result from these conditions. Drugs, toxins, and infections. Other causes of cirrhosis include drug reactions, prolonged exposure to toxic chemicals, parasitic infections, and repeated bouts of heart failure with liver congestion. What are the symptoms of cirrhosis? Many people with cirrhosis have no symptoms in the early stages of the disease. However, as the disease progresses, a person may experience the following symptoms: * weakness * fatigue * loss of appetite * nausea * vomiting * weight loss * abdominal pain and bloating when fluid accumulates in the abdomen * itching * spiderlike blood vessels on the skin What are the complications (EFFECTS) of cirrhosis? As liver function deteriorates, one or more complications may develop. In some people, complications may be the first signs of the disease. Edema and ascites. When liver damage progresses to an advanced stage, fluid collects in the legs, called edema, and in the abdomen, called ascites. Ascites can lead to bacterial peritonitis, a serious infection. Bruising and bleeding. When the liver slows or stops producing the proteins needed for blood clotting, a person will bruise or bleed easily. Portal hypertension. Normally, blood from the intestines and spleen is carried to the liver through the portal vein. But cirrhosis slows the normal flow of blood, which increases the pressure in the portal vein. This condition is called portal hypertension. Esophageal varices and gastropathy. When portal hypertension occurs, it may cause enlarged blood vessels in the esophagus, called varices, or in the stomach, called gastropathy, or both. Enlarged blood vessels are more likely to burst due to thin walls and increased pressure. If they burst, serious bleeding can occur in the esophagus or upper stomach, requiring immediate medical attention. Splenomegaly. When portal hypertension occurs, the spleen frequently enlarges and holds white blood cells and platelets, reducing the numbers of these cells in the blood. A low platelet count may be the first evidence that a person has developed cirrhosis. Jaundice. Jaundice occurs when the diseased liver does not remove enough bilirubin from the blood, causing yellowing of the skin and whites of the eyes and darkening of the urine. Bilirubin is the pigment that gives bile its reddish-yellow color. Gallstones. If cirrhosis prevents bile from flowing freely to and from the gallbladder, the bile hardens as gallstones. Sensitivity to medications. Cirrhosis slows the livers ability to filter medications from the blood. When this occurs, medications act longer than expected and build up in the body. This causes a person to be more sensitive to medications and their side effects. Hepatic encephalopathy. A failing liver cannot remove toxins from the blood, and they eventually accumulate in the brain. The buildup of toxins in the braincalled hepatic encephalopathycan decrease mental function and cause coma. Signs of decreased mental function include confusion, personality changes, memory loss, trouble concentrating, and a change in sleep habits. Insulin resistance and type 2 diabetes. Cirrhosis causes resistance to insulina hormone produced by the pancreas that enables the body to use glucose as energy. With insulin resistance, the bodys muscle, fat, and liver cells do not use insulin properly. The pancreas tries to keep up with the demand for insulin by producing more, but excess glucose builds up in the bloodstream causing type 2 diabetes. Liver cancer. Hepatocellular carcinoma is a type of liver cancer that can occur in people with cirrhosis. Hepatocellular carcinoma has a high mortality rate, but several treatment options are available. Other problems. Cirrhosis can cause immune system dysfunction, leading to the risk of infection. Cirrhosis can also cause kidney and lung failure, known as hepatorenal and hepatopulmonary syndromes. How is cirrhosis diagnosed? The diagnosis of cirrhosis is usually based on the presence of a risk factor for cirrhosis, such as alcohol use or obesity, and is confirmed by physical examination, blood tests, and imaging. The doctor will ask about the persons medical history and symptoms and perform a thorough physical examination to observe for clinical signs of the disease. For example, on abdominal examination, the liver may feel hard or enlarged with signs of ascites. The doctor will order blood tests that may be helpful in evaluating the liver and increasing the suspicion of cirrhosis. To view the liver for signs of enlargement, reduced blood flow, or ascites, the doctor may order a computerized tomography (CT) scan, ultrasound, magnetic resonance imaging (MRI), or liver scan. The doctor may look at the liver directly by inserting a laparoscope into the abdomen. A laparoscope is an instrument with a camera that relays pictures to a computer screen. A liver biopsy can confirm the diagnosis of cirrhosis but is not always necessary. A biopsy is usually done if the result might have an impact on treatment. The biopsy is performed with a needle inserted between the ribs or into a vein in the neck. Precautions are taken to minimize discomfort. A tiny sample of liver tissue is examined with a microscope for scarring or other signs of cirrhosis. Sometimes a cause of liver damage other than cirrhosis is found during biopsy. How is the severity of cirrhosis measured? The model for end-stage liver disease (MELD) score measures the severity of cirrhosis. The MELD score was developed to predict the 90-day survival of people with advanced cirrhosis. The MELD score is based on three blood tests: * international normalized ratio (INR)tests the clotting tendency of blood * bilirubintests the amount of bile pigment in the blood * creatininetests kidney function MELD scores usually range between 6 and 40, with a score of 6 indicating the best likelihood of 90-day survival. How is cirrhosis treated? Treatment for cirrhosis depends on the cause of the disease and whether complications are present. The goals of treatment are to slow the progression of scar tissue in the liver and prevent or treat the complications of the disease. Hospitalization may be necessary for cirrhosis with complications. Eating a nutritious diet. Because malnutrition is common in people with cirrhosis, a healthy diet is important in all stages of the disease. Health care providers recommend a meal plan that is well balanced. If ascites develops, a sodium-restricted diet is recommended. A person with cirrhosis should not eat raw shellfish, which can contain a bacterium that causes serious infection. To improve nutrition, the doctor may add a liquid supplement taken by mouth or through a nasogastric tubea tiny tube inserted through the nose and throat that reaches into the stomach. Avoiding alcohol and other substances. People with cirrhosis are encouraged not to consume any alcohol or illicit substances, as both will cause more liver damage. Because many vitamins and medicationsprescription and over-the-countercan affect liver function, a doctor should be consulted before taking them. Treatment for cirrhosis also addresses specific complications. For edema and ascites, the doctor will recommend diureticsmedications that remove fluid from the body. Large amounts of ascitic fluid may be removed from the abdomen and checked for bacterial peritonitis. Oral antibiotics may be prescribed to prevent infection. Severe infection with ascites will require intravenous (IV) antibiotics. The doctor may prescribe a beta-blocker or nitrate for portal hypertension. Beta-blockers can lower the pressure in the varices and reduce the risk of bleeding. Gastrointestinal bleeding requires an immediate upper endoscopy to look for esophageal varices. The doctor may perform a band-ligation using a special device to compress the varices and stop the bleeding. People who have had varices in the past may need to take medicine to prevent future episodes. Hepatic encephalopathy is treated by cleansing the bowel with lactulosea laxative given orally or in enemas. Antibiotics are added to the treatment if necessary. Patients may be asked to reduce dietary protein intake. Hepatic encephalopathy may improve as other complications of cirrhosis are controlled. Some people with cirrhosis who develop hepatorenal failure must undergo regular hemodialysis treatment, which uses a machine to clean wastes from the blood. Medications are also given to improve blood flow through the kidneys. Other treatments address the specific causes of cirrhosis. Treatment for cirrhosis caused by hepatitis depends on the specific type of hepatitis. For example, interferon and other antiviral drugs are prescribed for viral hepatitis, and autoimmune hepatitis requires corticosteroids and other drugs that suppress the immune system. Medications are given to treat various symptoms of cirrhosis, such as itching and abdominal pain. When is a liver transplant indicated for cirrhosis? A liver transplant is considered when complications cannot be controlled by treatment. Liver transplantation is a major operation in which the diseased liver is removed and replaced with a healthy one from an organ donor. A team of health professionals determines the risks and benefits of the procedure for each patient. Survival rates have improved over the past several years because of drugs that suppress the immune system and keep it from attacking and damaging the new liver. The number of people who need a liver transplant far exceeds the number of available organs. A person needing a transplant must go through a complicated evaluation process before being added to a long transplant waiting list. Generally, organs are given to people with the best chance of living the longest after a transplant. Survival after a transplant requires intensive follow-up and cooperation on the part of the patient and caregiver. Points to Remember Cirrhosis is a condition in which the liver slowly deteriorates and malfunctions due to chronic injury. Scar tissue replaces normal, healthy liver tissue, preventing the liver from working as it should. In the United States, heavy alcohol consumption and chronic hepatitis C have been the most common causes of cirrhosis. Obesity is becoming a common cause of cirrhosis, either as the sole cause or in combination with alcohol, hepatitis C, or both. Many people with cirrhosis have more than one cause of liver damage. Other causes of cirrhosis include hepatitis B, hepatitis D, and autoimmune hepatitis; diseases that damage or destroy bile ducts, inherited diseases, and nonalcoholic fatty liver disease; and drugs, toxins, and infections. Many people with cirrhosis have no symptoms in the early stages of the disease. As the disease progresses, symptoms may include weakness, fatigue, loss of appetite, nausea, vomiting, weight loss, abdominal pain and bloating, itching, and spiderlike blood vessels on the skin. As liver function deteriorates, one or more complications may develop. In some people, complications may be the first signs of the disease. The goals of treatment are to stop the progression of scar tissue in the liver and prevent or treat complications. Treatment for cirrhosis includes avoidance of alcohol and other drugs, nutrition therapy, and other therapies that treat specific complications or causes of the disease. Hospitalization may be necessary for cirrhosis with complications. A liver transplant is considered when complications of cirrhosis cannot be controlled by treatment. Hope through Research The National Institute of Diabetes and Digestive and Kidney Diseases Division of Digestive Diseases and Nutrition supports basic and clinical research into liver diseasesincluding cirrhosisand liver transplantation. Researchers are also studying the mechanisms of cirrhosis reversal in the early stages of the disease potential new approaches to the management of complications of cirrhosis the long-term outcome of new drugs to treat portal hypertension the development of therapies to prevent and treat the recurrence of hepatitis C after liver transplantation Participants in clinical trials can play a more active role in their own health care, gain access to new research treatments before they are widely available, and help others by contributing to medical research. For information about current studies, visit www.ClinicalTrials.gov. For More Information American Liver Foundation 75 Maiden Lane, Suite 603 New York, NY 100384810 Phone: 1800GOLIVER (4654837) or 2126681000 Fax: 2124838179 Email: info@liverfoundation.org Internet: www.liverfoundation.org Hepatitis Foundation International 504 Blick Drive Silver Spring, MD 209042901 Phone: 18008910707 or 3016224200 Fax: 3016224702 Email: hfi@comcast.net Internet: www.hepfi.orgUnited Network for Organ Sharing P.O. Box 2484 Richmond, VA 23218 Phone: 18888946361 or 8047824800 Fax: 8047824817 Internet: www.unos.org  The National Digestive Diseases Information Clearinghouse collects resource information about digestive diseases for the NIDDK Reference Collection. This database provides titles, abstracts, and availability information for health information and health education resources. You may view the results of the automatic search on cirrhosis. If you wish to perform your own search of the database, go to NIDDK Reference Collection. This publication may contain information about medications. When prepared, this publication included the most current information available. For updates or for questions about any medications, contact the U.S. Food and Drug Administration toll-free at 1888INFOFDA (4636332) or visit www.fda.gov. Consult your doctor for more information. Acknowledgments Publications produced by the Clearinghouse are carefully reviewed by both NIDDK scientists and outside experts. This publication was reviewed by Bruce A. Runyon, M.D., Loma Linda University Medical Center. National Digestive Diseases Information Clearinghouse 2 Information Way Bethesda, MD 208923570 Phone: 18008915389 TTY: 18665691162 Fax: 7037384929 Email: nddic@info.niddk.nih.gov Internet: www.digestive.niddk.nih.gov The National Digestive Diseases Information Clearinghouse (NDDIC) is a service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The NIDDK is part of the National Institutes of Health of the U.S. Department of Health and Human Services. Established in 1980, the Clearinghouse provides information about digestive diseases to people with digestive disorders and to their families, health care professionals, and the public. The NDDIC answers inquiries, develops and distributes publications, and works closely with professional and patient organizations and Government agencies to coordinate resources about digestive diseases. This publication is not copyrighted. The Clearinghouse encourages users of this publication to duplicate and distribute as many copies as desired. NIH Publication No. 091134 December 2008 < HYPERLINK "http://digestive.niddk.nih.gov/ddiseases/pubs/cirrhosis/" http://digestive.niddk.nih.gov/ddiseases/pubs/cirrhosis/>     PAGE  PAGE 7 /0C: ;  B . / 4 : F DajHpUisXYtʜv^.hj$}5>*ehfHq r7hj$}hG56>*ehfHq rhGhG5>*.hG5>*ehfHq rhGhG6jhGUmHnHu4hGhG5>*ehfHq rhG+hGhG5>*CJ(aJ(ehr$/0CD< = V : <   A B . / F G CD & FgdGgdG$a$gdGrVVijGHTUrsst,W & FgdGgdGWX|} " " # #$$|$}$%%&&((^)_)&* & FgdGgdGt~+} "" ##$$}$$%%&"'((_)m)&*B*//2 2=>AAH0HKKKjLL!MBMPPPQQUUUU5VɿɿɿɿɿɿɿɿɿɿɿɿͷɷɷɟɿɿɗjhGU.hj$}5>*ehfHq rhGhG5hGhG5>*hG4hGhG5>*ehfHq r.hG5>*ehfHq r7&*B*C*|,},--////00.1l11122 2!2M3N35566R8S8:gdG: :R;S;6<7<====>>??AAAABCDETFFqGGHHH & FgdGgdGH0H1H*I+IsIIIhJiJKKKKKKL'LGLiLjLLLLLL M!M $IfgdG & FgdGgdG!MBMPMcMMMMMMMNNhcccgdGkd$$IflF D*XXX t06    44 laytG $IfgdG NbOcOPPPPQQQQQRR6RLRpRRR-U.UUUUU)$$d%d&d'dNOPQa$gdGgdGUUrVtVuVwVxVzV{V}V~VVVVVVVVVh]hgdj$} &`#$gdma@5V6V7VoVpVrVsVuVvVxVyV{V|V~VVVVVVVVVVVVVVVÿɴÿhU0JmHnHuh|n h|n0Jjh|n0JUh ;jh ;UhGhGhG0JjhGUjZhma@U5 01h:pj$}/ =!"#$% n /l ʝZPw3PNG  IHDRZsRGBIDATx^w=R^A&DP@H 9z9ɒDC"9眃d$$ *F0\>/aNuO}pcf鮮Zg?}o=s屩ku6㴦cG_[75<)>[4V[jLKݝ`^^[ʍl7 w}4{G~G~~uh P艞ٟ=7~OO{Z_w=ٓ=@Ǯ|sck4j㱬KԟG d{{Ǐ}oo~w|G;JzzO~~ {pυ|W}#X|tO4{`8h_K><]jo?_a8. ~7w-̈'K{<8/-S/InL'jVD3{oͿ^m:#Za# VuκjqnqP)m=?9\[m:;PN8zt؅SF%y(XAk'mb]LJhqvVUmYfx{uSr{F6‡=S/*Ԝ׃+?*?*JE$ YW#`0ŶNv xztM\ge>3?:4:>zX x#cܫbof;kOv$#[ NC\'~'TNkgdGɫ}ɀݙy]y,q倭Q8޲V$?@0&ZZ8^{"z4OdF!Fb wO^awίp0NNuV&#zubsہM&B$7VYu0ϭK[B#(w\<-5ˤ-L9KwNC-EwV կ~FAݍM '3ڊ$X859Rޯ၃z-y@}kʌWzi=0Cf [m{U}*PS?k12& v0_M6^Vm-J=89Y( OWfDbUa- +G]]tz姆 ]51Z*4%]'ӅL,αLpk(+-wg Tor-JRL8phmo1J~6֨k}[]lUW\:q}`Ќ6 oNu`i'gway4[8QX̷vxrE)i6nAWᶸCW ?'$ M}fJ*J=p@Plwv|[O#ka]U rnU7aT] hl^vF%G=qZ席f<`[6s٨qN>TY5eq `/fCϹ]@@Wr$O$ՠWyZ2Ggx p?ɀo= u%JR8?gS>Sz8.5-m CE߸ ѻ-6ʽhH:?誊v]JtۅoQinnI5tZ5Ww~m=zot=^Ո[H[v=Y_+Rvtgk{y3Q9б|q`kW<;p{Eq-n$uзhe Z~l1`d1} / X}&5<}6=l:T=?g¶?g:Z*9~U=Œ+ U7ykkџ-2{P쫼ʫ4=NKd4U}_>p?@~gNU=ԕvC"aU0|77x3mo3:5݈{Lley~'35Cg"hzǁ>>_YB}UHޭ=_^uZ$(UVP fU+[RK ʁ0"ǨEn*2B//&|y8@64V`qEkgmlk;RR??3??ӭB嗭[m:iW@E<#oeأa| _5_U55V5MQPIӶE3nl "\S?SL=Qip{\a:7YDS<įz5(mC"iUn`ԕ(0dXmD-,fܥ1@[W~^gWɿ{D&W4M0v(bhsxT|} n1:d2[yDO / t 8k܎/Q?S=˽C.҂8eIhC=>hqջ? % _Z!*⻿~--V94)yovƁ%Wg8t?-p$%W>3=bɤYnqTCcWxk]}Xbqw4ߦ©vز~278Q߬e:z}6^?,=jh} BZ V(i׶Jɷ*.ٞ(El5O ]:W0 khT +FA3[ɳ; [_-T$!q?ӹE_EWrfBd`mthzVlu˝OP87=3?;7 ?^M UW } 3之W]U&j}Pп_ ʯg6@q0+j+<7CsJ|^tRxe"nS[F2˸jkߛ^ gD>zS\zv+T舾䕛0{=<k>L 媿S{!4hF4}n=lmmmh?qzT8[uԛ3*j7\.o認fQzItєV@ C-Pڪ-?iTu:__ϸ&OMI]PmjdM:w0YUꅫE"նy6V{4#Քfr|O{ߚ?F~u Ǝ߸Yϊ¡@0?<ח7,+_e{bGpdwJή3cUi [+_FmnUsO_Ź[lȟ΃jFW.k"|V^!ſ雾xӑFxe>lG~=ZI}t fֳ{oM'o @Y~e W4a~~w./b/Ɩѷ|˷p2os=sy@~r%I6`_E_74zd7~0OhM 07/|`_՘jx祖/s&R_|k@,g|ɲ0 u^[?iqչq] |7~#__PXZ+G+d'o>0GBیCt<]d#iJq9?vj G=+_5Ria!x(/ծ$ H!gfaw(f :Kʹ++?GH)8rIqJW$m͕$Zc%-zX|&[ i/MA9Fsk<JCPWxͭٚVV-OWa T@J`'f}I;<+D7I!jvfK.7}ux^):Wk$~eο,Y<[[H-eI-v(!P#<ΜOMCOy]^x 'y CP0e`&-#U%_#Ue>M}}䠵[gWLv/gz=2*7 ў=Rp_ ֭߫<3~0?>>-?|1UR3ʯ..ٟ gԩb· 7 B;οVjՠ71pkk w駭~Hŭte+ z9C2Mm'[_[@'8R(a|w~g0:Q;;rZHi FޅB&ozaNOpjx[fѠ{xtն#Hܺ4<<P1a/?鼊oo|;px\7,wY2`* 7r3_!8YbFCM4Wr١1MS{@如)rl1%>0twձ091WKˆٵ_ۏ '!BP_I|G}̪+)pYhdN F^!^>Vb q&pBe!>sAzxgakW,=<KLt,9]J0[f'! y7}7eK A><,6aaqȯʯ] OU_!x1?/D]x\wjUxOji{J[>m%4l%'ķ~%j k3JLp d;תX BOn !}%9wi(j?rFVeVnIZ8ݾ*|'['DP,`[zcWs^5؀T8z:9__z( ͭnbeQlmov,~{|~Ɖ#jhV׺"P; XfE`{H!tqM=!-X qݭҚ7-Zkk\妇p]ʡW[)VRlclD-4}͔c@|M$OBnkx{=ndo_}=7KW.ZJJTCv\'UMZ xJ-DiWnNW-mޣH܍G 'ya&ΡfQ+ٌy!"ܬ ̾?ʵ7|742Ĺ_e_;;}r[H 3s5qݧ7X\fEUZ*<2z}y`w ]i#ίBK&2=2~'| 4ȓo|x6'}'>ޱIzzL\9^/^ȃ?t`9夓;+ԸJ=G\F[b_ [ņ  ~.ź]lehuJVUxcd,: y='[RU_Uy-FVb_Qd;_>@gŁT[PEl,dn|{8(1_|5-n=-u%\sy0CSr}E}힄*W$:t $?8Ux˼˼ʫ <ceKQoL?(#ٞ=rGY :qL؂N/, 5}?׶qR͔7Njе{MHfuږؒH1%{ NNOoaal`,'eA[5J_~,Wh louuy\[  l9k{v8@bf[Y_wukINӊXY*x-]c 8$\.fW2ze^M;C:W+KӋxQTѶ^`5gtH-xLUDpq~Xך ^[ݴ8wd6 `^ #6Yp@αCqftDgvi3=@~́ΐvTt>nOo(LѮ.݅k=Wg:wA<{UGkrdkngbmL_߇5CjnŜ .o; :M-C.y>SR7'yɮ9sI.lY!lՂ}r%VHZ8wM;a Sl[ bgVߪhi(# X$tb?.׻s4 U [-mf΋Wo"T0eD]:g^3+T"[Cmr_8hhd# W+PPR`UY=T&b䦇4.5B`,r0ٽ{,V[ҪzxVfR ftG DВo!xb6Z QmѮh߫Jm7Mߚ 6z(+v_چiN'PYl€1a_ՍѸVSc4d7:LЄ}~mzxMkx{wkϯ`38qN 0Ϳ1հU/q,(TE7vZU3 @6( mpKkp?їUsί廦}i` Ͱ{K-᪕p!ܒĶfXw^b 8wH`8l~PbگJ!Uz+o<s >{+[u[+G݉ڮD1#fM3IlVX|ǽ xͬ\%>G}}U{ #?$(oT`WjkwA|0UW[V 9TtC*w|E0R"[uȓIPW=W4z|xkkOO~# kY=5Rɠ#Y>m[Z)yqP|f0[bK/'AGrGpw9y24*Ơ6V>X7Ҳy OOؘ z3^/'dop8ފZIN͛^jn9y\ ia"4:Ehvv؂T?@x˵e .Z~M͹BK03(|auzJW +FYͺ5SҰ{yV*}+;?%ӹ|ΐr e)kH=A~S%+@0WŖ ߀]܏|#Aq~N6J;42{{V\5ζ:oG~,;XB<$Crp9lcl+?De=W~+ l{{6e: 0µk̓xŰ\Rq"qh8\N_)F;rZN|&?*7yn\"IV۫WCI %mnWwJW u+<_~{r+X=pp;`ޭdm&9!^{M I5& ޹|W|ǜ54d։ PX>X=Z]Tȓ=x~mh Aj;AIC?`|xSBo\3.?ܿ's_1ԜgAXY!{04;ۚ#~gOGso-Hۓ'Zm4 4D?j,<] l:8#uqLc$wAAr8PZmҙn LѻUc)`h'}'%b9nkQa˼$fV2l[=(@ j-UlzN L CӕcM`[/@=6@Wڟ+*^!W1 *ؕEy>X؋y>mELEyj 1G6 #RWL3=ރ_7{7#ۣQ'5*>0j6pLuV-%.j[Mʼ1y7Ҩj +ӚmꦻZ3N8LQkyFj"oo0kkb'd֮?nADy*gg*v6wHMm0)߀dtzo+@UômNzk!Vl&baǭoBmUmn;AviZ76[[|z+_!T7 RfWh P?wQ <ߎڻv0BhaorJX…$%3k#8J_qND]o:K0V+ 5vmHjd)?M-P2r,[4 Bd8T&+j2?P&ՈNYǔ7~1BTIꙈ2x3vy)S??3[Dv ԰{Fv,>na=/626 n%!6)&!RI}=hkm:XnXY}cg5 Z|;;&ķxmMm;Oؐ ؏A$ 1:N~/bbi֒VƉn‡<[B]4yf.5=A!qY*  _[N;F-iᘛ`]c`%Ð,BvZƷVy~P@|.-zTmܚaxx m[a-an}5Rs+, 0lN묶T9?cWpYQ1 ̋YdDpӧBVAɫgz_Tt_k3[AV{dD6W|W'q?'0h]Nra[pmV7[ F5a@T£!pzh.qsB]oU/#0|$OOX5dwFIF4~ʹƶ=Uگ/qF‡h']tn c`H:nW}{|{Mփ|o@[7v[UKS?^<7;8# FS:|OzbzJ yq/w}w\1p<f~bWbFۛisՆ[1R84'C:8OP;y@/e9%[JPYF*>F qz"/gI\+T~fUn;\c]H1r3:QWRZÝܸgT:ZU҄ߌYn qw+t2; \O|^%mĀ)¤&_/jFB-SJU3keOc(Ǎ|F+]uhQ_mX+C9p0)-BSg[`zWRu#/mRZV"뾎|*N'ψF}#=ڄ[_-2h[X+4"Ӵ[^0]ۂ{T24z2ۨr>OtaLxsSVQYf=^!QOK޾w58b/?R|w|ȆKDy/΃|+ȖNyZQIH VQg֛3V u9 Nr *8caCr/r~wxA'Óꜷ!~ Wu@s3dыȠj̈́ûbum9ild|kVNk|8nf3wmCQ`.-6 y74a7ADBlD.43re誇{-ژHüAQ`,f9uGQlkk6LŻ X~ uml둳,A͏9WV +[]`;zhFݼ _vr)RWbѲҽDF^M 7%m3n-ګxjМè;2l} 22dIV abN|KRF ‏-=rw[|迡<Բ 6 /dklDQ8\f8_]3.ӲmmxI|BȨ4y2D졾 m ǙFf 8O/(`Mre= $C \Sl蒨&wF^Zt,;șBXl,ɛFƆ #<}ջ[]4cven1N$<-gmu7gȶ%~̅[wrǺr`PeZ@D x8};P9p@QVMi lr<@vȶD~\D5leCF\eU|ƶbRF,"g*G9Ajce]ҵt|56jl7֦[f+Ejp:J=@o`eoY 5_VW7PY-=tPfۼ۰BcxC" y`(6:^Bte?? '3`8xE'âKdLVX4kd+Zj; ͌Xe8juV٣.DoGŶh[+r-e1;V2QGg^yϾ KO"RU[ o5Ev~՝@1n mRNoLc('Pi/Ap7jdV4Ċ+ 5"-ܙτl\3n``1 ?WŦ܂mB~v8y$T==q o/D*Qfu jpZ*W hyѴ%Lxm+ dGoJp-|mcV0lV`++qKe K,K=f6 nb[9cieK<j mrmXVueuHV͆A_)01ߠU%ygz&f8DWLq qp|7}I@LiؖkE6^sAm;0m!ʣ'p!̦ǭiUJK2Z;%Z>Ɂ ?4A ̬w~7~cߘnFEu^u 8R zl]O::ʬkg&[O~R$ո=s&4[]O4 毛. }yltes;3BZ f|@RKͭz[0/'o܏ u'ϐZ;u4EI(˃FFKFS~M,&"A32VZ]k\rf]@Ն)V y//IFtLix=­=}ؕ{B o+(%׷-y qi3$ yS=Sч^bVw֜oo4)0w<=!_%Y}x8rCnɭGu+ Ӭ7 wC(3!v qz-.=b!fʭcB!b=r6du\j}ab*T8mBWlzK g.o=^j+RӅ-RWZ9tseU=ٓI''FK{1KG$ <] Aw }fՕתm@7[+(>(7bkj"cPTiHjkVm\YCPw@JNMILp]_-Vinڷ6;"{3* J/]!.O0_v=oCv-Fخ+\% +l&/$Ŋ6s]w5<~ zWm 6@0+. Wn_`#r{A5ɓ< y8""B/B hl7nR  3^u'ov&-pIHR`tWݪqjmBk%V5\yoU` N!^[O<4B]9C/1L<$tZGLgZ2P7)P(1!pO^j;2"2\ZIQ%Wu4ݎmFL(bRݑɦrWcVox]r[CE_E,F'34"w+5eV+/ݢa2/pܞlвEm_-W(ۗ WlZ]kൃnV2Oc}ڧ% "p|*Q8i=LmfwV*}C+WЛI./Q+zg pSY'9${ӻ kDODor{5#Y.HIn(G5ilzWйM$ۄåQi[+qj,H[C C]L۹Mkn͑cK V• ֜,MmO':3O~ j&n=h#Jj[)d%[Vh\kv|'ឩ6U R#p}r(lm DlU'ZjqK1\ϫ [D>{[|ak@y-[R'WIƙ6[K zuI3 DB\5: lWpJreWlI+T;UTo4ymc!s~ 4=_Y~g8sxk[%L ĭ$m{Td[0BCV3^;:;ܕ4q[8 lZle3P. ξ[>W~88#N>Xgd/>s&ϯ@s@G򙄍_k WW6I-ڑ"X] ݔ|XK.ȷf8bE![ON(>>3>Ë oV(p3}Gt[Zί8ϷLʃ }!jA.%GpwCR]guj T#wkPd5wzn5Ӿ[͐k]qFh'6 gYm9#P=&rީDZD{7іYn#Aim0`3hOU˧^|葏|Rw"Cpgƪ*,rC}aW$=C tOt^CI Ɩ܎D5cX8`{Q]ٞxbt_ço+r[S_u9]]NnۙZm}X"_koouu˵YkX is2c}'|B&˯Z!!@[˦meUԮr?`ξw6W9O-b{.JRF|\5nm1گ:ySDPlN=v;nm\2O4['n=zh 7V{=(x"nxxb5U.&Oh.D3jgvۭeV ξѝV\)s5U!8u4e+ShM0g5S-^pEp[< WUdNoo&wVY%YOİ|Ci7p@Xv{k@l4*F@ꇭՍ[yZ)9fN65 zj*=[{W& TlJ[ ⦤c>6ZQ=ng \5J{<+ `x${s`+Ӷ\qvtm*\I2+O8 {n0\܆y?rg X!1ϳouA smEYܚg,r,q0et`rL[XU:0q%wVDh>Xնu[W= q®H"6r$1;;~}//*9&t,Ym W˩` cDLĉ15wZ覆W^^6.+i%5FV`}e{޶nC|1kW[N #LOyyr6ÀjzM N6@f: R$SX"PɻKNJ›v+ <㬑* ܣ0V!>vW<&yWVofЋ؋}~3Uw 8y`=݊n`۽ݷ}۷svAy8ؒgY@Qc[OO_d#}!2b١їr`tvTKExoܰȠ9uTu[CXG[w4rܸ>9pK'Lx}} pDka8UWfUAL*|12Eab=J du(ϵQY il=y+qfֶ-`݊^xRZi>~,[SO9JBZ^߭IX! S`@D&a'Q{ëJX9kj;8zV[]]Bim'l8wxk+Uj|{9҈×/@n Pn^w3K%pXǶ-f9XV\zz.`rVAkr\;8PI˰~u-B}CWn:] BYAP':ەC`v|~.@fOlf[АFx#}QΓwӅAWgSGqxb,s6 V]|[Ǹ5m W%b0}F"+Ñ 7w+*jd9|cxT,<"F0,[",6,nLs5DvD88m䑎-ق:5pڡUi1&l7̑=[tHyvB_߄([ůh@)/*lC  Y/(g_+q9KwkZ?d(e'{hьޒGgsp^jNh+mn[qb7jXP3-p GۛiNcoGcpIÅg1@}9tѿKĄmG 0OkkEv%5V-dOԠ?wY9#;‡'mdhư`O+^Ψ;۸KzNܲ^rG<)G^Ƹ[xpQخyJ+"S;4A"ɨ`_iV[Q=oth,i)><0c}Ė,?SQ&˿}8v0#D~+9:xwxx,[ M,uދ==Ϊm_yvϷ kDYI+nzZ<&uKDh2̲cS-zuUo<||1, by{poL {9R¼Homq]2`7X6˷8`XFAsx.MN^ƓsUٹ.OTv#Tv]*So_ۊvd*Czԣȑs't 8u_} `9C; 5֜>T }f~6Pލo苾 7,=`RqFD>bY#I^^qr?ߩʯnŷr@}&e){}ܰuuq-i6ݷzbZC/ xd k4 fDYrj[_n*swLR3 s?s7+Ä?/a$9$7oQ|sU[?MC[gn$ݵwFȭGCCv{z{Um!m[zH}'|iݾUGv^ZW(-2s !/ȳ kO >o`SfZ,~/fؗ|ɗx-?~aРf0ÃpӾ7)B5-4Dwpl&u˷~׶}"dP#g+x8Vr+BsKls[?SS* epV@G_(EI$9##'kye}.Y:h");@C%[?ڨr-"]+mbt7^zsʶMd= =Kr2kFY:@g,ŷ f\zgoY&jZH+VHà cy JӶݢs[X- xy-5 ۶H"' aoo 5BmH c!@??L78 ,ʁceK8UЏ #ea'_l)+(Å߆.?MzH8>ͦUmx nP3|8n gh! !B%XdˏT;^-{ ~ ⍕N1?pMS ).fm9|lFI07D{0zJ_y ?.gd_~BDhSfɠUg uTEZ' ,LzVf~R?2lS B nEUC7w8-f*oO#ܩX`8\Մ'f6}B\% w7?\eIp䌿;% 02I/4]D#-mFPCPk8H6W%?l:O[7 .nc#Ikx6+;x]m4δEZo\k9-h '[i/U_-o eEgFq||Rпڊ]>lDz)&aq&p`Dxy[Pi*żwGewg[8C|Z\4)(GHD%WȮ:n3%UoA(<(ɰ.꯺ =biմ%LWJ]tW!>:zjŦl,0mڟќ? ̘|# (tɉ:8cTgv׀Ǒl^m|!?R7}7IVpJ _QξΛ$_a(6,ZHW*T+uH'DU;][Eru q &p,x!=C<1ٍ1h+7q/wa)݉|_f\Tlh@$>̑Ef  a1==-H/תP R ־Ar?L4YW"ÎŃ+顥 ,7<=Xte:QN…,W=s?7l7sIccοyUXjܓF6AhD?EtCtjaGL,ob+<"0T$(0#hnYbX+I5fU+st+Rb+_ngѱi|Q:zWk[L7Q du[WA{x$CxWڢIg~7W+#-1*289ޅt3J1Yj>jr,>.>ϳ Rr x僜鶴Msnc6f0ՐYGʇz7 jEģ+ݻ1cK#ƈW6=0ڰ{ 0|^@e8qË:5#@ٟͨtO6BM"!|:eT|CYJ3A~W{ŎWu/ R7~On0ݗU 8WHㅃ[)ԩhP8ߵʈ__-he`XUׁuglt\[|bnaQ8~=0ķB؍:Dԩc=d)i:m,7dwWC_*ו[V~2nKԃ솟n7ђ8y86K<9=-VZ`JBûw3[1S̸A-&__o1Qp4LX9MU\jW8 6p;\ۈRi 9lO'R<&4vk 5> ݕ.4yv6M{wgWnK1n46F>į7qz%LSkHrAP N ral`o-G-d*r,^v8otӨdcdO45ݡZ4?+5Z"ڗC̀Wjʽg2NPLf"ȕ?oB@!ooHD!Ә M7~4*@f1h l<80;b} >|C߶}p=mxb;KkeXB8N,NH&XǍN]*0Q+okB 'Xi;ΐ30jAֵ !CF)qD^%a ʉLx"xzy'T2۵?L4y,qΣy͚"wʱx|Ej+[Wi=984Qʉ[$V][lǙ~R'J%I+\EdyOQFыaApZ ϫ?̷wЃǫں S/߲xc J#W(bgvTi="i>U{ Yhл}Bk$H~[ܽan)/_SH&ѴMͤ ΅,x!#?ZsjWΊ'>nyWF`p;6+Pa!尗#,^;y5. EsG . hH//gW ob!CB*^Wd'|z={x1mpߵ_>Av)V¼W aa=#Z;IR+|Uڱ=CJtYsa.1B> /Tax?9@(g4"{1A0*<"L˳ '*̬ɫUd=]-V* *3*V/_ʯlTы6ane@"}0jQUN@=ևFK)v;(NK nnO@>gDSy"o d叇 Xn8]l} 锑{{)O.gȓjz `7WoYr^$rϳ<˳Ћl[;#kwvr.3 WpX|a֐9m:||dðzɈFC* x#̖ ( ,N"Z2D"Cp .giVoorX\3g倛SVn}{mm[(bpC Ўpǻ|inѼ9pm}DLt[AGbе*>~ 臮80Чrg%@ :7j9&8*WeHXv+Ls N>~_m@y,kp&k641XVX_}EpS}/𯁐-6T ;}=0+.Agw1U7 o^V)'Xʆ=ߓ̀Đ~NDNן4'mTco |:&e!ϰfF&-Q ;(/=gvxwf7JK8p+c}^uzf*\{Gr 07$wS*^C. ` `ʅlX†gxg| {d_Txc넿i|VGL$ ncyC * <>+iBd89Q ѩD D<+We܏vSanPLZQ!fۖH{VJolS6y:i@w3L3!5`zE`|5·qDM͖nݴd{a1d'q0weTJUH:"M ; RCwx | 5#QÃwav+U9U$Բ3`\NY"NTAwtS:BNAIz*Jt<׊*eL9/4a+rڬ20OvgEȨMx@垎5E2)d0"CС !2cGQ0Ҳ*ɻtjc8CC6 -ٌx? fGi ZaOX;W9BdKo OIL{BM=o>KLTeVr-qFϤ8X=%Ft" l.aZɷuc滬k˽˛+ˢLO Kg]VIYnj%=aJm !3 Qx;sq!f;+Zr=[- mU9$oj{6zt\KftLE*r z"sQ '"' 2aaՅT0sM ]OTO =$u0G78v τ<ʣFef^v<CE5bͱU2|l֒℅y>0[u{[WK-(ɁkމV0x9KPiI`꣧x6vfԩ4;X2s9w9])^$6T^6+W e0Ggwv:MHYRos-FSprޮ]U x"[X`Pչ=ۍmN}!t_oob>gNGQ{@t]o_ƿaƭ^.6ء@.&Z V`7ӽkUOQ^"?Uݥ{}mo*Ψ nm/MEЋ))6,VI2r &urS&1 x u?D1 mEa}]Y9mվnk( p^i P|Pۭ3-Ou MZ^b-MS,>.誯ڄ'V=Fs+X wHvۻ91^[az rsRH--57eOx[[B؏@9Wtc>c^E^Mh#:d!knt\jZK*FU<, W=YE z'B3.*((nᰌvlaŽ9'K+x84|Mߔ;$|䵀rֽh[. -`nF Cπp=Ei>-ymnR3!8W<?N c}+55AI|= Nm{b0;cD8"R>c:ǧVJvp\!$;\S\zf03+d-Xӆq?e%p*atvL=E"?w\Af ʁ/h&!n9 v:-|7̉О5dnBd8$O 0hbqQ Z] Rɴ>i+>w}(~& tee; Ӈl[W|By=ߔG5k8ezG2\2x+!s7%gn8@ "A?%F"AIq$fҦ7Y: !uEu͜Kq?wDo*Id6"WM.'DbЁC)r2?W%tWX?Gñ9qU!.4Nn!Kɍm%1$!2R5MTΆ'@3!N HK̓입 .Ͽ8(d:i%kCe>C>#f<-P- E&Bl( {u5́^_w+-2e:J# ssj,;?G$tS|dU Яb&h?F(˃l{?WZCNQ! AfcgQb ~"Z*[d$''X,P) x|w+LQ` |f 3-:NV*(D -14ĝtQzaLgRO@N8VͲQc 4@X4LVh *f__A3N7[Q75h %_ݍkm莅qc:@&D07Or@ͪ9}WI 2ż6g)|X!Nmj(_C?6?2\p|]]2rP;~z+1/i_Ȇʜ|S`(lX6d7lZކ5:mn *vH2#-W{d֟V셄,IrГ΀*vV1)`H'V`#>oPh c1u^p;;hP!\eКB353$P<08#Fy5vyp~_r8ˢL%SvpFWt(yӨb73|V.?76_D`E7? „Q{v׿RLfx+ _ "h]`e_ea/&.$|vOlrGF\H<"LLI(j Ϧ DD6 OGXEyz5'{<Ɋ@(A.ǎf//LLoaMo&:ICqgW檑I"W88Í["+ڸ?RŊ9p@[[Ἢ8ߞ)C$mL /21"O.̨$leP~.sɮ&HHI&6f"țDMc{&$8u]v 0v׀|}J:Kr?\{L#(a,}wdk/! T ?Iͭ8UB Rw t!_"YODt\1 =Z M1_<¥Ny ^\>4Mĥ.*HIL:c _|YT"R5.'/='d3S("sf0`各dy gӴE$gd]R܈b1,(U,Vh 10*ܚrۺݞDhD9UPdm^"& Z[_}Җ:%DA|ʧʥ7HDfb> 5UR:lV_cλ d(tVU4/NI3 y--9Mڵdˁ.IGL@,$>ViuQh!s~R&pvf,PI0q{W?O-ZTL|1,"<ܙR̓C+!JsQJw㡾!Ox,Ob,ɛ "MI1%&$SnzaQ/Nf #HTۑ؆`=ra•7Z- ?!Cʺ wi0zP@1V?XE!Dj%przDŽh#^F\L'>{U9 TҾz٣SEUwZ(k{X dP|fۓ+ũ!G47lybrm%) ᨍ/%@W3[e![qS!tf3"ݶ*" k7[ңd ;\ YЪౡ ؂ H'pDk`XI!Nxk) itنN{^K-*\W8èvT2nFC@ׂwFPCx$gؕթYBSs_mէ]N Oukپ[!Dϳ;ЏI$lKL<7?q?T`E☽8U-{b}m*J& u˦H>SIj&g9Bیu.5o5bZ2VZ y,a/OwhΒ#;bDlS1ugTcKҤۏZPo3 F`N )[FɝA~؁6\٩ ^*ړUYІL i`.Fs4aP(h3<]vl@B<|ɗd3 @6IT݂`d Q8]j c,3pCHC%X #wNTY {<-&NC Ͳ@":^ klc_p'ɁrփfV~!եc__|Ca`M=:Ϻ UiNd23 i3 !~rP`J@{EgD |cuB{?*o X7n6ݎYzz|tӢ3V;튳-Dp %}n=bsA~#>ARx&̈́e Ĝhh S^DmX B/e;Av3qԮGcKVyMGp,z)# cz-ǎI,3 ZeC3-ib tmQ, anC\VOHt;R'\l 恃!oe9" e8Ob\USl.%&W 3EPl M@$,^EMV-8&eXH3Qpa=#gxfJb Rt2a5*h<Cx&sT&⪨C{ +dB!I$Ż]/rʵ2<v+#cy9'1Jx$RCttD-1%_%MN fﵡ6`&_&mWIl.7 qP^G!槳I2EMq&BȄN7y9KTWGs]]x{u,0DƔJ36P䄿8VVk|oQ7p6ķk7j$S;C\R6Bo;jUGdA$,:\g2Sr2ܠg >N'È%5!.GVzLyRا^:Fy$A?6A6P)4~˭< Ś-R2 JzQ`h{AzЕ1TBG'(܃L6S n4.n4bA҇)Ub:8W{W#@v#:+bI΃rqH,N߫t!B+4"b`^ S2y qQ;7rS`݆3|gq2H>izۅX b {]ŗӵDVؤjy dblLbJ;l {DO9]Ùy,[V[7ܽ kaQRi@(巜qwYd#X78ڛb__ +UIqoBX@Nd]d#5J1V0i!IfF/4N6'WAYmt]%b[<ٗۊmpMeHɇ`?sZ{K:H ƙN_Gl_aYKCDdc(1<pΩ`p+;C9$Z$9gy"fW*慤Vz)30CkDG lnI=%g 2caI.2Ë ҺGelk|{23mS $oy]D4%X6>s㢩 |sv#;PY^0`:ƎVIRIN+c*C| h3KZxq^v8A?$͑}fpX?p-۪Xad0qX|a}o!T͍,WrIҐ3n@-G!U#0i'yGײSm Oś\W֐yK2t8"K~⇩gkV jyߴ9 yDhv9B{(t_1R0!]Saa^yG.}17z- 7-Tk`־1Hрut Y|vs> ؒQ|~JbG<#k* Y$XQy{P+5vsv|V|h~_18JNC q 2ԒPi=s!߽_j}Y!~{achf kF8 NEZp/>xU~¬PMhs5O77g ֆ@ E]pTw!M9_ ~rE~ˤ? T0X6 asLNgL`f"=U DDތ `2 bT9=\VM9r2ܥ@aIB f3 :4'73,֜r_ik?3vZrbiČfMФkpOfDL7 C!=C䪾nݚ<܃)  2e)Tc;HF/jD1wA)g2!ߔLR!~q}VϞr! DGSnuP0jqGkH-FU43_lLawv;[OD,y~]wPfK@11'FgLDnf N<a<$.sbV\H(``Gk"}ͳiqŵ]6=$@᱁(qͫ> 3^RV$!+uZ TѥPvccR" #ANyES,n:) e 6j[0x gxXvd|면т* V\@[~$Vc᰻:S]UhT En/b+㕖0$j@e^v WfɆ M+Z,|!;k&3d HṡQI :UUb)C٘Px ۳?*X9+! hύXVB Q.iRrc;v%9Ϧ4!* P癰_lq%2Wml{iuPi tIh2%kF==Q"3^pA`:N [jLnL pT.$ ;,>b"|[{Yn7H:h@ߣɨB{'8&q kDqVᜧ&f{saP9 s81 0 ƕg983Dn^m:bQf k]Hվj b9A=y\|CFsZE(WE(y)7g9B"_`آ2'f  үHlP<| ?cȠ~V zcJԱz8Rzb3D8VPg OedX.U -[Gq 0Rpfã/Ejҕdž?c-ggڶLrECJ&KUP ؒ3 Ehg`6&N ak)F 堹GHNۖ k5@,*s ;^l+㭦vBk6VWɖsfpv$R$_@+j.C1^31Ai5Q=7бH5@RWl%pkpLya{>>MEӯ,nSʈWp1m1:rW~DZ%ӄ FNbT@?C:E%~'W溏-avΠS+fF;j3FQ 6ߦӨ^42V-Q<5$o}eH,o oUtm&jp[Z֢{8+Dk+qe"<^/:0 mGB6P2M0ai55w=M-LȾ{Uy7ԕ:O_"@"t: A5uPG3Y3ƀWv,B6_qGDzRsy˜}62Zh&Pa('۟ɀ>IeFi+ J8w ?0Ȉ0Qo&9?!٬7^R PNiZ^[p9ȱ8 b푙MF<20>Qpm [Fqi;$ FDٲ´mDr| oiPώ-7t2mU}۩expT U$ \e uxVKVy<[xFkRV=d9FÑU =T)W! XIU w $vV6stewbdIr6Ӓ&o_uƊUՐn5UmH*S<4{c+ioVvxd=KRM5h +,H}7<ڎG;?T->`KmV<9vl}GX]'1ϸ$,>̀:JaB#ӷaÖ\۸/F9CLkQ3a8> ^i:c6 ^[إmΤ\};;a%;ѡjZ< d-9'P96l54ann_%v~#U&x+A`ıS-I)! Eyju u"> hRqg|vmk$Tڕ yz Yr=\YY)^ȶG&'<ډˉ4(I]eU51 6팟mޟ*|l`y1Dc$RPma{(^*HU[YS &`-b$`Qdf :Q= zJsie8̆x^9Rw_I.Rˎ'YFIn$>4sQiCGSV(7)Hxs\рZf=׮&mX}m#fform'(nzrbjns5Aju8\x<1-s7`̀-c 7ZUWh^/dOP P5A/y,<ݎZ iˤ!XF8Ÿې -]-t\"iumu6$}TcDNpAyn?) %1;,ٕ/Ұ;!x;i]60jAH9o:W'z{ )&7wӄP5K ƍzwyOtjdd`}u(0&O0ֳ=SIpRV۾4_mswKB*+ߣs0mUCv!{m D6bu:ウ(QbKmn0|=BZƢwBOAX9edΙr2'xGF5=݌<y4Ԟ05^D]%ˇFŜ)T s eeB2V7ߙ8; `}=X^:'9( Y?4n3TbB}M7WƤg̚'Z8k{dܔ(:$iQ\:´DҼbB+}sGeYؐb|P%U) 6K!6& D_ 8'e͒))08oLĊ<&HcdG2-!Bp @sx"vp CòN\d.1aLcohV>3/"tsËy\S(Ng'@8 qXAx0a~;`3r܃xxߛQVtXξ[R 聣X\⃒ț&9 Q0 ԓxA j;Eڧg!:R`˩c3f#C!ʜ}k#6Dp0khƣ[|84E9Џ9c$*KwFRfKW(ق;g {dQNa,2i#z]Uî!ql8)>#Tmx>;7hɁ 'R%HOL e(MI4}n2;2}fAG020D]^cИ`J34M/l[]2HX ]!@0jD>Eד1pX:aΒ ѸI( M֟-vWfk$< @y؎ c=Nyh|S;I7L^a .4Z FIݐ%c.8hOF> '/pSypBP21̺ZEhCҞtFߣyPM1yn.Qab3ya4J-X;yF7`¢̣1: h'[\IR78'}i7[Ȏd1dG;l;Ή0\I$or6!z³ʃZDC hMs$19q uŅȃC4PQnD`xg9i~DPJ^G$u㌉$ 0V.\%IAve#Ib^4HŐMș inâ\¼irOS\V j΁#F:( M+a qb3YZ& zhr`w{Bq[2PmXoԊePZ~v=*=??;xm6*diVQI_̷HjNMbJ HDX`xJr4OUd ' AHO$ЀSXRD@<͐hwU rUx!Lf!y8@p3E.M-2 u&6``;ɨP 똀룍ܹ絆dm,;XY~E T3IE|TFZq߮fKO\Y5߁q+;/@WT0᳻$zyu [q4c=q5`c=\Y2,c*(O4*! >5`LdOXdRmQ@ 8g|-tH@vɽ?WnW5ƬDnXv1`yGrLh!u+L-c<ԑ2T QUsd0(28N"uϻi]\j^@= l"@ #Vkݠ պC0(1m71ûFW `"b!DN1b3e_uޙ$!dg$7C"qft@$էЭ2D;PT#k9&]>#uc[48%z*ܾOO<KVM+ksFuIR J0@T{y!&-Hr$N*|pHP?؏A!"U8q.d -dxxv*K+:8FL0HkHD>t5Zўn tP OG,\Skh+̖/cљE3R@]-Nm~zr^N7%)wHj|PZ<ƑI̔h>{wy+R1@8IZ , ADƈ-DcQE7o?^'?7 Dչ`.1W.I., jAvӟ#&|1`qFkLV@E<skVmXu 9(VSİ7?V/70`eW`iu`؂jIG ؚ fČ(>n6fC.v"P8xM('c`}sM_7Ox#?#i3,$9@']LQ @Ntd0yR%}1U$Gca)l.{LYǓ`9s6g)-S3}-Df1,d6) kT_U@dsd䘶.lAy@`'S9&'B\dL=D|NLgIRjQq $_ƲhNsҸa EM0>c;Naj#@"v'-2ߠ- ~ GrӧF ax)ؔ.Q~ñ-"Ik j9$]@fVޮe00\ cS9[nOSon?iK/ p`JBB!$ ۜIzy+{ ؏Dڦ 2}̌PQSvagKמþ! !Y1;X|g\Y|x^ErfΒTuIK#d, b/jűSRC 2Crd߹ L 5r&v1<Ml+])uL~HD:F7c :)&9bEdceRZȈAٓnr;- "p =&ihp{!mCMDxeJ0"*Bl'cA9DDil.a*-7(hn(F;pvm 1N"Ս`41 s_P9K ̛᰺NCF8I̷;4P"1#3zI>K#߳ep%0+(p`3ٰ{aVP q2Eؽ_}V80 ;\y9Չ8Il%S:lj7yqYse!r*gm J6štp.dLˁ`m؍TnIdń:RW҅=o |c{@wD$O;-*?*8%CT"XAor3$ :o'0+#vJNuӸ9(vL,`"a1)sV gW= |6,ZP0BoHR/= ~!Ɛ|3"!6Tb<Mҋv$JٸW ~:NL=`n.8軺*tJz3, [җGY哈?Ñ MC\H`F'S% 1#]͖W 6y1,,0]ǽP֜w#cwQwS!yLV h.kOVe刔u‚}Ԃ'#kXD\K܅4hZDb> 5beOh9dIO2ͱ&0 ]5ؖVP5P%{>36١0Q;6;' 9(~*odʲ&]6Gm86V7x2$ᄩIr k1|L!+q fAMʤowrt^pۖdj]&+im* EЮnCIP`k/oځι-9L%s2x[H|dɖ~j䎎qю&Zs?Qg$tރֵlmG~z,xG,r0^U#`u$al2.˃1bNCUAp6}͆Jf`\r?Q2+K<Z0QXÝjV.u|?BMª*},2)&C5Q'8MXمB?&LdY睈˫ $kN2\70w Qܜ1;B3P` Qu 7\ERXҎO@vniQtF%xmB}g,%9Ñw3}v[K7X-`%ъ|VjQE 5C+OYε.`0s=Tf^ ?ȉV18%dS |6Lb 6<Nx%T$Zp$'g$ XF4O22A1 dEKȦQ Ta4b[|cxN7R]ucxIqt,gD)B$Drj3# :2ppZX<٪.n@@ؠnj N:y!QBk4k1VaV1|u?X' Nl~$HX2~N~WL(pǦ91"ذ Qteܭצcz2d* {T?=O*߸7|L׬\y`ʸ [ Y*e+kFŴP5|R[`vTfC49s2&H9cVkA?ϓgG!O.-GqV ><#4gWW} Pf{R Fe &m#~%jo~#2è ]|~t:?Ug@JFcޕXJ9WA%z.Sw%nyˁ85@?YPfIBmFFjMǴ\3X=>9Fޫ  v2餐<1!5QMdda<\m(ꒃ=s!/obgE:C>@ jŀ-2sEՁ4T"X0q`zEC_[FsWhZx˦mgL=gh0&!pU h&% 17E@ɓ)S H)M*XC+ Օ#LNk V:1nq!#se2!a%'kl:QJ&I,x%9d4Va/!n50 co/0s2aP7el& bQJZ]iR~_ |NFɅg|n%f|yh땈HeфHY99ҾtZaFuhc|40ŁB.)_8 a{{24d˿n%Ȕ Es)=,%Ԧȏ $f x%GKA >3?ݐl,-܎L|U@d ݮK9*e`t!B$!vi\Yaa3뜌F$b 0490 Cec= fZ̔wb#7F_"Z%2}'0 l$!E%#e^wNB ( t;7/8œϛBK@*B֍͎O }% !3ReC c2w׊2 Q#be_MLQ#eh Osqƣf=G,C+\C=#'II@7@`$CWr&TB кJ 'lspAG{NeWf<=hWT@鼫7,!yYOq%!ʫ&K@Μ BG3 t0 3;Dpcq SR AV9N9_ gWǹ6hhdRӖV Hov(ױJ@{ψŭ-Mpnxj`ԣ3OCQh,>&f  ,%[t ұ["qDőusZ]/0!G&BJvqS7J~.UY e3#;x#YBwWPM77'(,"4уY @^\0ߥr1V8sM!E媈D@^:H>,:..M܌ٽhHs&^x9P~ 3H7 ̴{iP{X\&RxFU*H7Z>@c^o!h n I~aQnU$&S|H0D)F%@,t-Od #a0߮& bXJX\C]*O5Wy'(-}C]Y!̱O1!A<^tbC[|J `ԎۗA'W1)b}\b 6L$EpIo5"LjD`[x^VX< P)SRZXH%cII[)G׮YFI7a2tydH(9y@a3'# %ϝfQ# 0PKq#*)EM%LOiotSJfsM|3\U}\jWȨFs0W'tD\[zkByx6#s63et9*Q $ ÒMR|' ܃49ixSMND<;y/-BX k '=D>$"РɉjHD0 \r F F4JC`zL1'Ы 1( {翍4'!USn㸸+ɾ0-gá ŕqۍ'0BVΐ@69v@ƌd}ӕO?/n6}I:1ָ[Y ψ'2!-D8<"8f|jQ*h=!)C% !"g[0ĭZ$1q4kؒ6݃p#?F-o6<+NQ0]VXi=|pQL Zn!"NfaT$,)Ux|֠ IpMDz@%BS4sb:X8U !IG?M-D[ tm~60}>【Fݣ%_OEWŧ&WqL1fC49]tF(zh%K6ʑlnQONeढ:ɨ1"rI z`HõuP8#Ї)Xlg>Pad?i_0> 9-˷2P⠹ XNbVǂX>.4>@FFkr 5,8|si4 },2;7)^rWYb>b,FffOd@;TE''ūn!!A` &>s3>Î4!c!?OmGk6Wr̟@Cd"=:aԇ1r Jdy@Y"aC($f_vS!J$NMLjY 6PYlw1C "K7.He $X\CU`Gl< Uحwj+'c0"9f͸vm!n\7ͮioxDr`*1C\5%)2_x +ZaRJ6abȌ ,$mtS2t/$Q '"; Ԡ*s&N". Ig7CY͇D|響 {): p c~df>\/Uh3L 2q* zu.Ň>J6׎MaR2/b3ml)͸ mw7/~cDbu^տ6MIGL%&FY>EHQ=ZCdLEF$qsɈ},̳SC}H i3;!O `C/TJJ%,$rw}2[ 0EO7 ASqŽK`׏~bomkfg(e~c*14 !*V"ږrKDv6y6,bWe-f01c̜NBx8gQa|8R6tKvÔITjЊ]\F蝉ZjklH#sAXb2mw&=P!) 1N)-Q8ciq,bi @ @]agn$ L,!v/jDj #eU2juI\h='<܂,;'T`#|ȇ { jI,S؟_ổe_E| H &$<=ϟCʭOo}C;T  =dzοo'@倌.5"{̐Cŷ;XVXZJDə$dKDmn?-SdE߹(1sPVYeV-sЖA؋91cHys}֦ <ˢ(e&@8ʠZM3gjNGaǨkJVu$a }j[CKP;.k; "ܾAK}m>?ܖ(pX.}j0dkA,y6`~"Ġ[e?1X6 H@1d YO7횗3F y#3hPNgTRGdD G%2DroQ<3:=%sJ}:!;7x /:HȐ :ԣ=l(υw2bc>}BН7d•`+b=8*hOqHkQ x[$AjIY`g Q s%cַ]2no^6]F5pQka3 B$vN&D010&ip.,։>zIyF-Og"(A9jqF@@> ”Zr{uЛvD3 vӒ6O[i2TNF"D^{+rw de&bTZievڇW@4lJ(b$C3)v G<~)F<&|7"P?ͧփT9'@B0Mp$]. 2?p_k=>aۥm5j/Zڨ{8K_ܵ'I<4x5.9iygTDD;jC*(g%P~7Y_{6,+d0mҭkq0gd)3i /X`Aq 8CݜD/ $/Rcp?Aރi"_8!;|R'Q`.lmPcB< 9]_*8;u<`AnXl*[hF3c,W8pUgC^aw]9wu%~[ƥ o]+}m }7k - .ށ[RQ/%s p<5s s@q5& JLɄp0CCoXA1l bsOcrV Y"rƩ͸Pۃ-8>Άl\'my(π~ZG'۶Bx ^} pD)ĵ>y3"?)ebS@V4|6f/X/?n^z-"9q#}шW;||+vWj~Ⴉ|hBkWG?[C<%"GAh9M+84J.p /eӄv"3QJBc˔ȝi&}m4)Y/ɯϺ)TCZ壐4T:K!tB=vr=B?M__!z~һq<*UP/G&E $׼w.ABN.I~hni~86aP:vS헩a@C~s O{CD6*}gG2DzD"L" D) zĵ6 BMh+9U /Bxu氌JX2xJ)RTq֚zSᾞw.c]pe NlVd3)%Qu P@v/¥cma)SKh3\bi5JM!ovp|tsqthp4rph5Sfwt.uw.Yo:Q潧 zYڭ ,rG >jpQ8F/ZRܪR &aӪk z|1Dv9+ڮ_A.c\L"r''P+A0͇aGZ"WV0]51ldlHiC. @ˍgb|SPBh,5+[P0%'JLS@1$ʊe^FeČ.ib@'j=(UH!aR+8ÀKm)jUz[-A{OS/9‹bf/ b:Lpq<70vxQB$`FgSIBd(`KPgw0ӷ o"4AL-~8aP=. 0ބ=HQ2v6viV8Y܂O]}W%2! |յMjrY. .d}Oz[{g.P9Q\%^/3Knl0+Zn],-$@mfcVq`][lXx`cO1tcq[bӷ+pfx4? r^iwͅ[>r؍)1, `i}8.N,03^4zP;^%br*͍VlQz! .@JHҎXU 9x?LuQ,Hv0RT_Ahy|}4 "a7L7u!1($jW!)oh,L븕 `Y/c5:0ley:q=cc1Y%ҊRBU1L+8[8wr4c|) /qpB7P"|.~_(lij|iaa]V&5S ~i  %@YiHKSӌcLp#*OjMҌ\VWgC&YG΀ Tt?s^50̭lՉ'D[/vM0-<]JvBJ+21%('C'!WJ\+'F؎ oPtvb{|v3PufVpߡsZ"N[HZ4abcTDlC;,CmHAnM#]`7~yhl[dORXxd0dG(_u#'!M156%Q%SK#ɨoxTSo{i{U)Mz-\Wï &R&K4)Clٶ~sՒEq6of3՞/,4^am9=/C{CrP-@ \lGY{3Z;b|Bî?⑼ )GBVg+L9 "%#SGZ +ujbʞzϪW.jG`t C<`ȆtU‰U 񩚄 ]i{VSWkM?SɳL="H(Kk~'`qc$Dî9F\a2-[@iT `U"/Kq-ݛjnNQ$%˙]& J>G̘ʩUQ{3?(]}Ts%-ۚ,K}m 7F.Ĥ@Xky@ (3Lւ0XINK1d=OL!HXٓE<]SSE^NQR$YA7%7lX4` oQf9f6MNŸ&,,V8IP{ڲ:6>WB:kݶyМ\#'` ʬWF[H#XGg%è\h  s*K‘H >R3d*Q=wʄm h]@Tۖ>ԣ IDAThTh52OeBĐU]( C6SC9^nuQޭHXdS4UKdJ=i '5gu@e9Ҳe6|aH& bNQ ;ƎCRF@x,Krx6 B4!YY"R @7," Cy"ԸbKp0L`şWvx|elXDņ|b:.Lԃej{mDL9r :>ZJhXXeu9.Kmӓ]l)֝7fW" wi?J8Y(Ra`[׀'ojLĄ0 ĵ5+dhyNb02Ղ+"(71̣|V9^یW{cxSU(($CC46m ;Տ٦pH"=䖽>YƨlSfU&sQ8i}BtbU9Vҙ%,NȚ`*YBO# 2a&S%"c0O=ZפAG B0u󶡓(KqO )"7Œ6uF/V`Iay&;s$Ahd`1[N[[D H[֍Ϸ >VKńKfCg%%?$Lsr%'5fRs®'Z;tel|j`/=hmq%iC:("a4ҳc $- ӡ)װI0 hȦF![鈘{%**).O jY w蒩Yׄ(<nm. D ݗKfUX?g-)xHg)U\#p1 Dwjo(|9|$X/ ܎$7t \6ʬm7m]{)o U|GNؙUݿrf]!sy~}' }Nی ַLT0K;} ḡ,KO-|\&RP(\SĎ!;<Ŋu9XieD'.([_K6.M-L|B2||ل@C0SfZ+"qrʏxwI)XщE,Oȷ6y6ܷ )8eK(7Ԋ9DoZ1~ikS6ߪfnJ|pͧ 9͇On{څrYOќ*Q&r_Ok;+s&~y/Oug R%%e.զ9 DUQ>єV` (C,W"/& J/s5CU$eȪ+2$Y\TLr_Ke$r_.G:uX_A*B*ph4@4 j$}Header  !.)@!. j$} Page NumberNr/0CD<=V:<AB./FGCD i j G H T U rsst,WX|}    |} ^!_!&"B"C"|$}$%%''''((.)l)))** *!*M+N+--..R0S02 2R3S36474555566779999:;<=T>>q??@@@0@1@*A+AsAAAhBiBCCCCCCD'DGDiDjDDDDDD E!EBEPEcEEEEEEEFFbGcGHHHHIIIIIJJ6JLJpJJJ-M.MMMMMMrNtNuNwNxNzN{N}N~NNNNNNNN00000000000000000000000000 00 00 00 00 00 00 00 00000000000000000000 00 00 00 00 00 00 00 00 00 0 0 0 0 0 0000000000000000000000000000000000000000000000 0  0  0 0 0 0 0 0 0000000 0 0 0 0000000000000 0000000 0000000 0 00000000000000000000000000000X0000X0000X0000X0000X00X00X00@0@00 0by00:<MMMMMNZ00Z00Z00Z00X 0XZ0HX0X0X00X0X 00Y $$$$$'t5VV,18W&*:H!MNUV-/0234567V.M6NoNNX  '!!l,b$/l ʝZPw3 7r@(  J  # A"`B S  ?:N.+T$8 Dk> 9 k> : 4l> ; tl> < 4m> = Ln> > n> ? g= @ g= A ,h= B i= C i= D l= E 4m= F m= G $q= H q= I 4r= J  s= K s= L s= M t= N Tt= O t= P t= Q u= R Tu= S u= T u= U w= V *urn:schemas-microsoft-com:office:smarttags PostalCode:*urn:schemas-microsoft-com:office:smarttagsStreet9*urn:schemas-microsoft-com:office:smarttagsState;*urn:schemas-microsoft-com:office:smarttagsaddress=*urn:schemas-microsoft-com:office:smarttags PlaceType= *urn:schemas-microsoft-com:office:smarttags PlaceNameB#*urn:schemas-microsoft-com:office:smarttagscountry-region9$*urn:schemas-microsoft-com:office:smarttagsplace8!*urn:schemas-microsoft-com:office:smarttagsCity >$#$!$#$!$!$!$ $!BHbj,34;$+ %0 U^ !!" ""#$$$4)=)r)|)!,(,(-3-//{//0&000K1R11111^2g2z3333DDHHHHHHMqNrNrNtNtNuNuNwNxNzN{N}N~NNNNNNmn-z2< ((4)>)r)})N+g+--MqNrNrNtNtNuNuNwNxNzN{N}N~NNNNNN33333333333333333330Dn/GDc&"C"*!*99@1@CCjDD EBEEEHHIIMpNqNrNrNtNtNuNuNwNxNzN{N}N~NNNnnXY&"&"HHMpNqNrNsNtNtNuNvNwNyNzN|N}N~NNNNNNWS^ '4.>ELNSE8pX3u4hhh^h`OJQJo(hHh88^8`OJQJ^Jo(hHoh^`OJQJo(hHh  ^ `OJQJo(hHh  ^ `OJQJ^Jo(hHohxx^x`OJQJo(hHhHH^H`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHvh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHhhh^h`OJQJo(hHh88^8`OJQJ^Jo(hHoh^`OJQJo(hHh  ^ `OJQJo(hHh  ^ `OJQJ^Jo(hHohxx^x`OJQJo(hHhHH^H`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHvh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hH'3uWS.>8pELN                                             Dw     J;wddwUG ;ma@j$}|nCjD!EEEN@0 N@UnknownG: Times New Roman5Symbol3& : Arial?5 z Courier New;Wingdings"1h&& B( B(!4JNJN 2QHX ?G2.The CAUSES & EFFECTS of CIRRHOSIS of the LIVER AdministratorStephen Housenick$      Oh+'0  8D d p |0The CAUSES & EFFECTS of CIRRHOSIS of the LIVERAdministratorNormalStephen Housenick2Microsoft Office Word@F#@9س@9س B՜.+,D՜.+,` hp  IITS(JN' /The CAUSES & EFFECTS of CIRRHOSIS of the LIVER Title 8@ _PID_HLINKSANF9http://digestive.niddk.nih.gov/ddiseases/pubs/cirrhosis/!  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry F:سData 1TableIWordDocument9|SummaryInformation(DocumentSummaryInformation8CompObjq  FMicrosoft Office Word Document MSWordDocWord.Document.89q